NO841780L - Fremgangsmaate for fremstilling av nye pyrimidon-derivater - Google Patents
Fremgangsmaate for fremstilling av nye pyrimidon-derivaterInfo
- Publication number
- NO841780L NO841780L NO841780A NO841780A NO841780L NO 841780 L NO841780 L NO 841780L NO 841780 A NO841780 A NO 841780A NO 841780 A NO841780 A NO 841780A NO 841780 L NO841780 L NO 841780L
- Authority
- NO
- Norway
- Prior art keywords
- dimethoxy
- pyrimido
- isoquinolin
- formula
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 3
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
- -1 methylenedioxy Chemical group 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 24
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 150000008318 pyrimidones Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- ZBYXKMWAPJNVTP-KRWDZBQOSA-N (6s)-2-(2,6-dimethylanilino)-6-ethyl-9,10-dimethoxy-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@@H](N1C(=O)N=2)CC)C3=CC(OC)=C(OC)C=C3C1=CC=2NC1=C(C)C=CC=C1C ZBYXKMWAPJNVTP-KRWDZBQOSA-N 0.000 claims description 3
- NKBFMQFLIHCOGI-HNNXBMFYSA-N (6s)-2-(2,6-dimethylanilino)-9,10-dimethoxy-6-methyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound N=1C(=O)N([C@@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC=1NC1=C(C)C=CC=C1C NKBFMQFLIHCOGI-HNNXBMFYSA-N 0.000 claims description 3
- ZPHDEHCTDNLLOW-SFHVURJKSA-N (6s)-6-ethyl-9,10-dimethoxy-2-(2,4,6-trimethylanilino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@@H](N1C(=O)N=2)CC)C3=CC(OC)=C(OC)C=C3C1=CC=2NC1=C(C)C=C(C)C=C1C ZPHDEHCTDNLLOW-SFHVURJKSA-N 0.000 claims description 3
- ULCVGPWVTYPDDM-KRWDZBQOSA-N (7r)-9,10-dimethoxy-3,7-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@H](C)C=1C=C(C(=CC=11)OC)OC)N(C(N2C)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C ULCVGPWVTYPDDM-KRWDZBQOSA-N 0.000 claims description 3
- VRDZFQAUAFYRDQ-UHFFFAOYSA-N 9,10-dimethoxy-6-methyl-2-(2,4,6-trimethylanilino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)N(C(N=2)=O)C1=CC=2NC1=C(C)C=C(C)C=C1C VRDZFQAUAFYRDQ-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- ZGCRHLLZAJECST-SFHVURJKSA-N (6s)-2-(2,6-dimethylphenyl)imino-6-ethyl-9,10-dimethoxy-3-methyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@@H](N1C(=O)N2C)CC)C3=CC(OC)=C(OC)C=C3C1=CC2=NC1=C(C)C=CC=C1C ZGCRHLLZAJECST-SFHVURJKSA-N 0.000 claims description 2
- RSODZRSTCNUQGQ-KRWDZBQOSA-N (6s)-9,10-dimethoxy-3,6-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C(=O)N([C@@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC1=NC1=C(C)C=C(C)C=C1C RSODZRSTCNUQGQ-KRWDZBQOSA-N 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229940125898 compound 5 Drugs 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000010992 reflux Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- CUBGKVUFGAQIFL-INIZCTEOSA-N (6s)-2-(2,6-dimethylphenyl)imino-9,10-dimethoxy-3,6-dimethyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C(=O)N([C@@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC1=NC1=C(C)C=CC=C1C CUBGKVUFGAQIFL-INIZCTEOSA-N 0.000 description 2
- ZAYQQSOIFXBLKS-IBGZPJMESA-N (6s)-6-ethyl-9,10-dimethoxy-3-methyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@@H](N1C(=O)N2C)CC)C3=CC(OC)=C(OC)C=C3C1=CC2=NC1=C(C)C=C(C)C=C1C ZAYQQSOIFXBLKS-IBGZPJMESA-N 0.000 description 2
- YHEXEOXHXZWOTH-VIFPVBQESA-N 1-[(2s)-1-(3,4-dimethoxyphenyl)propan-2-yl]-1,3-diazinane-2,4,6-trione Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H](C)N1C(=O)NC(=O)CC1=O YHEXEOXHXZWOTH-VIFPVBQESA-N 0.000 description 2
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IHUBFBNARXNUEQ-UHFFFAOYSA-N 9,10-dimethoxy-7,7-dimethyl-2-(2,4,6-trimethylanilino)-6h-pyrimido[6,1-a]isoquinolin-4-one Chemical compound N=1C(=O)N2CC(C)(C)C=3C=C(OC)C(OC)=CC=3C2=CC=1NC1=C(C)C=C(C)C=C1C IHUBFBNARXNUEQ-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229910001503 inorganic bromide Inorganic materials 0.000 description 2
- 229910001504 inorganic chloride Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000002829 nitrogen Chemical class 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- KAZPHAGSWZTKDW-MRVPVSSYSA-N (2r)-1-(3,4-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC=C(C[C@@H](C)N)C=C1OC KAZPHAGSWZTKDW-MRVPVSSYSA-N 0.000 description 1
- FLPWBPAEWBUYLL-JTQLQIEISA-N (2s)-1-(3,4-dimethoxyphenyl)butan-2-amine Chemical compound CC[C@H](N)CC1=CC=C(OC)C(OC)=C1 FLPWBPAEWBUYLL-JTQLQIEISA-N 0.000 description 1
- KAZPHAGSWZTKDW-QMMMGPOBSA-N (2s)-1-(3,4-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC=C(C[C@H](C)N)C=C1OC KAZPHAGSWZTKDW-QMMMGPOBSA-N 0.000 description 1
- SZTJRKJVRLTIDX-UHFFFAOYSA-N (3,4-dimethoxyphenyl)urea Chemical compound COC1=CC=C(NC(N)=O)C=C1OC SZTJRKJVRLTIDX-UHFFFAOYSA-N 0.000 description 1
- RSODZRSTCNUQGQ-QGZVFWFLSA-N (6r)-9,10-dimethoxy-3,6-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C(=O)N([C@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC1=NC1=C(C)C=C(C)C=C1C RSODZRSTCNUQGQ-QGZVFWFLSA-N 0.000 description 1
- VRDZFQAUAFYRDQ-MRXNPFEDSA-N (6r)-9,10-dimethoxy-6-methyl-2-(2,4,6-trimethylanilino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound N=1C(=O)N([C@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC=1NC1=C(C)C=C(C)C=C1C VRDZFQAUAFYRDQ-MRXNPFEDSA-N 0.000 description 1
- VRDZFQAUAFYRDQ-INIZCTEOSA-N (6s)-9,10-dimethoxy-6-methyl-2-(2,4,6-trimethylanilino)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound N=1C(=O)N([C@@H](C)CC=2C=C(C(=CC=22)OC)OC)C2=CC=1NC1=C(C)C=C(C)C=C1C VRDZFQAUAFYRDQ-INIZCTEOSA-N 0.000 description 1
- ULCVGPWVTYPDDM-QGZVFWFLSA-N (7s)-9,10-dimethoxy-3,7-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C([C@@H](C)C=1C=C(C(=CC=11)OC)OC)N(C(N2C)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C ULCVGPWVTYPDDM-QGZVFWFLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DHLWJXGSZDJWKK-UHFFFAOYSA-N 1-(2,3-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC=CC(CC(C)N)=C1OC DHLWJXGSZDJWKK-UHFFFAOYSA-N 0.000 description 1
- FLPWBPAEWBUYLL-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)butan-2-amine Chemical compound CCC(N)CC1=CC=C(OC)C(OC)=C1 FLPWBPAEWBUYLL-UHFFFAOYSA-N 0.000 description 1
- KAZPHAGSWZTKDW-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)propan-2-amine Chemical compound COC1=CC=C(CC(C)N)C=C1OC KAZPHAGSWZTKDW-UHFFFAOYSA-N 0.000 description 1
- YXIKCDJZGLTUEO-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)propan-2-ylurea Chemical compound COC1=CC=C(CC(C)NC(N)=O)C=C1OC YXIKCDJZGLTUEO-UHFFFAOYSA-N 0.000 description 1
- YHEXEOXHXZWOTH-SECBINFHSA-N 1-[(2r)-1-(3,4-dimethoxyphenyl)propan-2-yl]-1,3-diazinane-2,4,6-trione Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H](C)N1C(=O)NC(=O)CC1=O YHEXEOXHXZWOTH-SECBINFHSA-N 0.000 description 1
- CPQKRZNVDGKMQW-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]-5-methyl-1,3-diazinane-2,4,6-trione Chemical compound C1=C(OC)C(OC)=CC=C1CCN1C(=O)C(C)C(=O)NC1=O CPQKRZNVDGKMQW-UHFFFAOYSA-N 0.000 description 1
- RBSGPLGNQFXTEQ-UHFFFAOYSA-N 1-[3-(3,4-dimethoxyphenyl)propyl]-1,3-diazinane-2,4,6-trione Chemical compound C1=C(OC)C(OC)=CC=C1CCCN1C(=O)NC(=O)CC1=O RBSGPLGNQFXTEQ-UHFFFAOYSA-N 0.000 description 1
- BZZKABPYTXDJQF-UHFFFAOYSA-N 1-benzazepin-4-one Chemical compound O=C1C=CN=C2C=CC=CC2=C1 BZZKABPYTXDJQF-UHFFFAOYSA-N 0.000 description 1
- ZMNFJHUGGAOPNI-UHFFFAOYSA-N 10-methoxy-3,7,7-trimethyl-2-(2,4,6-trimethylphenyl)imino-6h-pyrimido[6,1-a]isoquinolin-4-one Chemical compound C=1C(OC)=CC=C(C(CN2C(=O)N3C)(C)C)C=1C2=CC3=NC1=C(C)C=C(C)C=C1C ZMNFJHUGGAOPNI-UHFFFAOYSA-N 0.000 description 1
- KWVPRPSXBZNOHS-UHFFFAOYSA-N 2,4,6-Trimethylaniline Chemical compound CC1=CC(C)=C(N)C(C)=C1 KWVPRPSXBZNOHS-UHFFFAOYSA-N 0.000 description 1
- LUICYNZUMXJHFO-UHFFFAOYSA-N 2-(2,4-dimethylanilino)-9,10-dimethoxy-7-methyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)CN(C(N=2)=O)C1=CC=2NC1=CC=C(C)C=C1C LUICYNZUMXJHFO-UHFFFAOYSA-N 0.000 description 1
- JPCCKVQVJCYNDG-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)imino-9,10-dimethoxy-3,7-dimethyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)CN(C(N2C)=O)C1=CC2=NC1=CC=C(C)C=C1C JPCCKVQVJCYNDG-UHFFFAOYSA-N 0.000 description 1
- MDAOEGJTBPQGCB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)ethylurea Chemical compound COC1=CC=C(CCNC(N)=O)C=C1OC MDAOEGJTBPQGCB-UHFFFAOYSA-N 0.000 description 1
- KZOWYUSBBFDUDR-UHFFFAOYSA-N 2-(3,5-dimethoxyanilino)-9,10-dimethoxy-7-methyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC(OC)=CC(NC2=NC(=O)N3CC(C)C4=CC(OC)=C(OC)C=C4C3=C2)=C1 KZOWYUSBBFDUDR-UHFFFAOYSA-N 0.000 description 1
- SIZKMOMFVSYOLC-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)imino-9,10-dimethoxy-3,7-dimethyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound COC1=CC(OC)=CC(N=C2N(C(=O)N3CC(C)C4=CC(OC)=C(OC)C=C4C3=C2)C)=C1 SIZKMOMFVSYOLC-UHFFFAOYSA-N 0.000 description 1
- TWIRNJZVYLPWCN-UHFFFAOYSA-N 2-(4,5-dimethoxy-5-methylcyclohexa-1,3-dien-1-yl)ethanamine Chemical compound CC1(CC(=CC=C1OC)CCN)OC TWIRNJZVYLPWCN-UHFFFAOYSA-N 0.000 description 1
- APUNMXONFPEDOB-UHFFFAOYSA-N 2-(4-fluoroanilino)-9,10-dimethoxy-7-methyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)CN(C(N=2)=O)C1=CC=2NC1=CC=C(F)C=C1 APUNMXONFPEDOB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- XZGIXSLHJDKMKM-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)butan-1-amine Chemical compound COC1=CC=C(C(C)CCN)C=C1OC XZGIXSLHJDKMKM-UHFFFAOYSA-N 0.000 description 1
- REDIVKCRDWMSQC-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)butan-2-amine Chemical compound COC1=CC=C(C(C)C(C)N)C=C1OC REDIVKCRDWMSQC-UHFFFAOYSA-N 0.000 description 1
- WYYQSKUMIFPNFW-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)propan-1-amine Chemical compound COC1=CC=C(CCCN)C=C1OC WYYQSKUMIFPNFW-UHFFFAOYSA-N 0.000 description 1
- LTWAXDIHUBZVCW-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)propylurea Chemical compound COC1=CC=C(CCCNC(N)=O)C=C1OC LTWAXDIHUBZVCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DZOKENUNRMDZCS-UHFFFAOYSA-N 3h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)CN=CC2=C1 DZOKENUNRMDZCS-UHFFFAOYSA-N 0.000 description 1
- YGSWJGUMQLOPOZ-UHFFFAOYSA-N 5-[1-(3,4-dimethoxyphenyl)propan-2-yl]-1,3-diazinane-2,4,6-trione Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)C1C(=O)NC(=O)NC1=O YGSWJGUMQLOPOZ-UHFFFAOYSA-N 0.000 description 1
- YXQVGAUSIWXAPE-UHFFFAOYSA-N 9,10-dimethoxy-1,3-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2C)=O)C1=C(C)C2=NC1=C(C)C=C(C)C=C1C YXQVGAUSIWXAPE-UHFFFAOYSA-N 0.000 description 1
- ZVPHNQYSKIGVJU-UHFFFAOYSA-N 9,10-dimethoxy-2-(4-methoxyphenyl)imino-3,7-dimethyl-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=CC(OC)=CC=C1N=C1N(C)C(=O)N2CC(C)C3=CC(OC)=C(OC)C=C3C2=C1 ZVPHNQYSKIGVJU-UHFFFAOYSA-N 0.000 description 1
- RSODZRSTCNUQGQ-UHFFFAOYSA-N 9,10-dimethoxy-3,6-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)N(C(N2C)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C RSODZRSTCNUQGQ-UHFFFAOYSA-N 0.000 description 1
- OJTPNRQOKSMXOT-UHFFFAOYSA-N 9,10-dimethoxy-3,7,7-trimethyl-2-(2,4,6-trimethylphenyl)imino-6h-pyrimido[6,1-a]isoquinolin-4-one Chemical compound CN1C(=O)N2CC(C)(C)C=3C=C(OC)C(OC)=CC=3C2=CC1=NC1=C(C)C=C(C)C=C1C OJTPNRQOKSMXOT-UHFFFAOYSA-N 0.000 description 1
- ULCVGPWVTYPDDM-UHFFFAOYSA-N 9,10-dimethoxy-3,7-dimethyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)CN(C(N2C)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C ULCVGPWVTYPDDM-UHFFFAOYSA-N 0.000 description 1
- HYXKTCIWUKHUBS-UHFFFAOYSA-N 9,10-dimethoxy-3,7-dimethyl-2-(3,4,5-trimethoxyphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)CN(C(N2C)=O)C1=CC2=NC1=CC(OC)=C(OC)C(OC)=C1 HYXKTCIWUKHUBS-UHFFFAOYSA-N 0.000 description 1
- SFGAWJATIORJKM-UHFFFAOYSA-N 9,10-dimethoxy-7-methyl-3-propyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound CCCN1C(=O)N2CC(C)C3=CC(OC)=C(OC)C=C3C2=CC1=NC1=C(C)C=C(C)C=C1C SFGAWJATIORJKM-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PKXADSMBZJCAGK-UHFFFAOYSA-N Cl.C1=CC=C2C(=O)CN=CC2=C1 Chemical compound Cl.C1=CC=C2C(=O)CN=CC2=C1 PKXADSMBZJCAGK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- QCULXSKMELOHKV-JTQLQIEISA-N [(2s)-1-(3,4-dimethoxyphenyl)butan-2-yl]urea Chemical compound NC(=O)N[C@@H](CC)CC1=CC=C(OC)C(OC)=C1 QCULXSKMELOHKV-JTQLQIEISA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000007656 barbituric acids Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Denne oppfinnelse angår en fremgangsmåte for fremstilling av nye pyrimidon-derivater som er egnet for anvendelse i farma-søytiske preparater.
De nye pyrimidon-derivater er forbindelser med formelen
hvor n betyr tallet 1 eller 0,
1 2
X, A og A betyr eventuelt mono- eller di-lavere-alkylert metylen,
eller X betyr eventuelt lavere-alkylert nitrogen,
R betyr hydrogen eller lavere-alkyl og Y sammen med Z betyr en gruppe =NR^,
eller R sammen med Z betyr en N-C-binding, og Y betyr en gruppe -N(H)R<5>,
1 2 3
R , R og R betyr hydrogen, lavere-alkyl eller lavere-alkoksy,
12 3
eller to nabostilte R , R eller R betyr metylendioksy eller etylendioksy,
R<4>betyr hydrogen eller lavere-alkyl,
R 5 betyr fenyl som eventuelt er substituert med R 6 , R 7ogR<8>,
6 7 8
R , R og R betyr klor, fluor, brom, lavere-alkyl eller
-alkoksy,
i det hvis R er hydrogen og n = 0, er minst én av metylen-1 2
gruppene A og A mono- eller di-lavare-alkylert,
og fysiologisk forlikelige salter derav.
Det her anvendte uttrykk "lavere" betegner lineære eller forgrenete rester med 1-6, fortrinnsvis 1-4, C-atomer, såsom metyl, etyl, propyl, isopropyl, n-butyl og isobutyl, samt alkoksyrester svarende til disse alkylrester. Av klor, fluor og brom foretrekkes førstnevnte.
De nye pyrimidon-derivater kan inneholde ett eller flere asymmetriske karbonatomer og kan således foreligge som optisk aktive enantiomerer som diastereomerer eller som recemater. Videre kan de nye pyrimidon-derivater, særlig de forbindelser med formel I og salter derav hvor R betyr hydrogen og Y sammen med Z en gruppe =NR<5>, eller hvor R sammen med Z betyr en N-C-binding og Y en gruppe -N(H)R^, foreligge i forskjellige tauto-mere former. Disse enantiomerer, diastereomerer, racemater og tautomerer kan likeledes fremstilles ifølge oppfinnelsen.
Forbindelsene med formel I danner salter med syrer, som likeledes kan fremstilles ifølge oppfinnelsen. Eksempler på slike salter er salter med fysiologisk forlikelige mineralsyrer såsom saltsyre, bromhydrogensyre, svovelsyre og fosforsyre; eller med organiske syrer såsom metansulfonsyre, eddiksyre, propionsyre, sitronsyre, ravsyre, eplesyre, fumarsyre, fenyl-eddiksyre eller salicylsyre.
Blant de nye pyrimidon-derivater foretrekkes de hvor R1
2 3
betyr hydrogen og R og R betyr lavere-alkoksy, særlig metoksy, i para-stilling til de angulære C-atomer i fenylringen; X, A<1>
og A 2betyr eventuelt mono- eller dimetylert metylen, eller X
6 7 8
eventuelt metylert nitrogen; resp. R , R og R betyr klor,
brom, lavare-alkyl eller -alkoksy.
Videre foretrekkes forbindelse med formel I hvor n er 0 eller 1, X er metylen, en av A<1>og A<2>er metylen og den annen er monometylert metylen, særlig slike hvor C-atomet i en mono-metylert metylengruppe A 1 har R-konfigurasjonen resp. C-atomet i en monometylert metylengruppe A 2 har S-konfigurasjonen, og dessuten slike hvor R er hydrogen eller metyl eller R sammen med Z danner en N-C-binding, samt slike hvor R 4 er hydrogen resp.
R^ mesityl eller 2,6-xylyl.
Spesielt foretrekkes de nye pyrimidon-derivater hvor R1
2 3
er hydrogen og R og R lavere-alkoksy, særlig metoksy, i para-stilling til de angulære C-atomer i fenylringen, n er 0 eller 1,
1 2
X er metylen, en av A A er metylen og den annen er monometylert metylen, idet C-atomet i en monometylert metylengruppe A^ har R-konfigurasjonen resp. C-atomet i en monometylert metylengruppe A 2 har S-konfigurasjonen, R er hydrogen eller metyl, eller
4 5
R sammen med Z danner en N-C-binding, R er hydrogen og R er mesityl eller 2,6-xylyl, særlig de følgende forbindelser: (S)-9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isokinolin-4-on,
(S)-6-etyl-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-4H-pyrimido[6,1- a] isokinolin-4-on,
(S)-6-etyl-9,10-dimetoksy-2-mesitylimino-3-metyl-2,3,6,7-tetrahydro-4H-pyrimido [6,1- a] isokinolin-4-on,
(S)-6-etyl-6,7-dihydro-9,10-dimetoksy-2-(2,6-xilidino)-4H-pyrimido[6,1-a] isokinolin-4-on,
(S)-6-etyl-9,10-dimetoksy-3-metyl-2,3,6, 7-tetrahydro-2-(2,6-zylylimino)-4H-pyrimido ^6 ,1-a]isokinolin-4-on,
6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido [_ 6 ,1 -a]] isokinolin-4-on,
9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a^ isokinolin-4-on,
10,11-dimetoksy-2-mesitylimino-3-metyl-2,3,6,7-tetrahydro-4H, 6H-pyrimido [_6 ,1 - a] benzazepin-4on,
(S)-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido [_6 ,1 -a] isokinolin-4-on,
(S)-6,7-dihydro-9,10-dimetoksy-6-metyl-2-(2,6-xylidino)-4H-pyrimido[6,1-a]isokinolin-4-on,
(S)-9,10-dimetoksy-3,6-dimetyl-2,3,6,7-tetrahydro-2-(2,6-xylylimino)-4H-pyrimido[6,1-a] isokinolin-4-on, og
(R)-9,10-dimetoksy-3,7-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido [6 ,1-a]isokinolin-4-on.
De nye forbindelser kan fremstilles ved at
a) en forbindelse med formelen
hvor Y' er klor eller brom, og de øvrige symboler har den
ovenfor angitte betydning,
omsettes med et amin med formelen R^Nf^, hvor R^ har den ovenfor angitte betydning,
b) en fremstilt forbindelse med formel I, hvor R betyr hydrogen, og Y smamen med Z er en gruppe =NR~<*>, eller hvor R sammen 5 5 med Z danner en N-C-binding og Y er en gruppe -N(H)R , og R har den ovenfor angitte betydning, omsettet eventuelt med et lavere-alkylhalogenid, c) produktet fra trinn a) eller b) isoleres i form av en fri base med formel I eller et fysilogisk forlikelig salt derav.
Fremgangsmåtetrinn a) kan utføres i et oppløsningsmiddel, fortrinnsvis et aprotisk oppløsningsmiddel såsom et halogenert hydrokarbon, f.eks. kloroform, hensiktsmessig i nærvær av en base, såsom tri-(lavere-alkyl)-amin, f.eks. trietylamin, eller et alkalimetallkarbonat, f.eks. Na2^- 0^ eller I^CO^, ved en temperatur opp til reaksjonsblandingens tilbakeløpstemperatur. Derved oppnås forbindelser med formel I hvor R betyr hydrogen, og Y smamen med Z betyr en gruppe =NR<5>, eller hvor R sammen med Z betyr en N-C-binding, og Y en gruppe -N(H)R 5 , og R 5 har den ovenfor angitte betydning.
Det eventuelle fremgangsmåtetrinn b) kan utføres i et polart oppløsningsmiddel, såsom et keton, f.eks. aceton, eller et amid, f.eks. dimetylformamid, ved en temperatur opp til reaksjonsblandingens tilbakeløpstemperatur, fortrinnsvis ved ca. 100°C, hensiktsmessig i nærvær av en base, såsom et alkalimetallkarbonat eller et hindret, tertiært amin, såsom et tri-(lavere-alkyl)-amin, f.eks. trietylamin. Derved oppnås forbindelser med formel I hvor R betyr lavere-alkyl, og Y sammen med Z er en gruppe
5 5
= NR , og R har den ovenfor angitte betydning.
Utgangspyrimidonene med formel II kan fremstilles ved at
en forbindelse med formelen
12 14 hvor n, X, A , A og R - R har den ovenfor angitte betydning , omsettes med et uorganisk syreklorid eller -bromid, eller et passende uorganisk klorid eller bromid. Denne omsetning kan foretas med et uorganisk syreklord eller -bromid, såsom POCl^, POBr^ eller S0C12, ved en temperatur opp til reaksjonsblandingens tilbakeløpstemperatur, eller med et uorganisk klorid eller bromid svarende til syrekloridet eller -bromidet, såsom PC15, ved en temperatur opp til ca. 100°C. Barbitursyre-derivatene med formel III kan fremstilles ved
å gå ut fra de tilsvarende aminer med formelen
over urinstoff-derivatene med formelen
12 13
hvor n,X,A,A og R -R har den ovenfor angitte betydning .
Hensiktsmessig omsettes et amin med formel IV med et alkaliiso-cyanat, f.eks. natriumusocyanat, i nærvær av en uorganisk syre såsom saltsyre, i et vandig, protisk oppløsningsmiddel såsom en alkohol, f.eks. etanol. Man kan derefter omsette det oppnådde urinstoff-derivat med formel V med et malonsyre-derivat med
4 6 4
formelen R CH(COOR )-, hvor R har den ovenfor angitte betydning, og R 6er lavere-alkyl, f.eks. med malonsyredietylester, i en alkohol, såsom metanol eller etanol, i nærvær av et alkalimetall-alkoholat, f.eks. natriummetanolat eller -etanolat.
Aminene med formel IV er kjente eller kan fremstilles på i og for seg kjent måte, f.eks. som beskrevet i J-Med. Chem. 16, 1973, 480 eller i Tetrahedron 31, 1975, 2595.
De nye pyrimidon-derivater kan anvendes som legemidler.
De hemmer aggregasjonen av blodplater og kan derfor anvendes til å lindre tromboser. Dessuten er de kretsløp-virksomme, særlig antihypertensivt virksomme, og kan anvendes til behandling resp. forhindring av kardiovaskulære lidelser.
De nye pyrimidon-derivater kan anvendes som legemidler, f.eks. i form av farmasøytiske preparater, som inneholder derivatene eller deres salter i blanding med et for enteral, perkutan eller parenteral anvendelse egnet farmasøytisk, organisk eller uorganisk inert bæremateriale, f.eks. vann, gelatin,
gummi arabikum, melkesukker, stivelse, magnesiumstearat, talk, planteoljer, polyalkylenlgykoler eller vaseliner. De farma-søytiske preparater kan foreligge i fast form, f.eks. som tablet-ter, dragéer, stikkpiller, kapsler; i halvfast form, f.eks. som salver; eller i flytende form, f.eks. som oppløsninger, suspensjoner eller emulsjoner. Eventuelt er de sterilisert og/eller inneholder hjelpestoffer såsom konserverings-, stabiliserings-, fukte- eller emulgeringsmidler, salter for forandring av de osmotiske trykk eller buffere. De kan også inneholde andre
terapeutisk verdifulle stoffer.
Oral administrering av de nye pyrimidon-derivater foretrekkes. For voksne anvendes en oral daglig dose på 0,1 til 30 mg/kg og en parenteral daglig dose på 0,01 til 10 mg/kg, i hvert til-felle under hensyntagen til de individuelle behov hos pasientene og administreringsformen.
Den aggregasjonshemmende virkning ble påvist ved aggrego-meter-metoden (Nature 194, 1962, 927; 231, 1971, 220). Den maksi-male aggregasjonshastighet ble tatt som forsøksparameter, og den effektive konsentrasjon (EC,-q) ble funnet ut fra dose-virknings-kurven. Blodplaterikt plasme fra mennesker ble oppnådd fra citrat-behandlet veneblod ved sentrifugering. Forsøkene ble foretatt med suspensjoner av prøveforbindelsene i 0,9% NaCl.
0,18 ml citratplasma ble tilsatt 10 yl suspensjon av prøvefor-bindelsen og inkubert i 10 min. ved 37°C, hvorpå aggregasjonen ble igangsatt ved tilsetning av 10 yl av en suspensjon av kolla-genfibriller. For hydrokloridene av produktene ifølge noen av de nedenstående eksempler, ble de følgende EC^Q-verdier (i yM) funnet:
9,10-dimetoksy-3,7-dimetyl-2-(o-tolylimino)-2,3,6,7-tetra-hydro-4H-pyrimido [6,1-a^ isokinolin-4-on-hydroklorid (produktet fra eksempel 6a)2) har en LD5q på 2500 mg/kg p.o. på mus.
Eksempel 1
A. Fremstilling av utgangsmaterialet
a) 0,3 mol 3,4-dimetoksy-3-metylfenetylamin oppløses i 300 ml etanol og tilsettes 0,3 mol 1N saltsyre. Ved 50°C tilsetter man
derefter porsjonsvis ialt 0,31 mol natriumisocyanat i løpet av 90 min. Ved avkjøling utkrystalliserer urinstoff-derivatet som svarer til utgangsaminet. Rent (3,4-dimetoksy-3-metylfenetyl)-urinstoff frafiltreres og vaskes med kaldt vann. smp. 179-180°C.
b) 7,25 g natrium oppløses i 420 ml etanol. Til denne oppløs- ning settes 0,315 mol malonsyredietylester, fulgt av 0,3 mol (3,4-dimetoksy-B-metylfenetyl)urinstoff (oppløst i 250 ml etanol). Blandingen kokes i 20 timer under tilbakeløpskjøling, avkjøles derefter og tilsettes 500 ml 1N saltsyre. Den utfelte 1 -(3,4-dimetoksy-3-metylfenetyl)barbitursyre frafUtreres og vaskes med vandig etanol..smp. 85-96°C. c) 0,1 mol 1-(3,4-dimetoksy-3-metylfenetyl)barbitursyre opp-løses i 300 ml fosforoksyklorid og kokes i 18 timer under til-bakeløpskj øling . Oppløsningen inndampes, og residuet opptas i en blanding av is, vann og kloroform og innstilles på pH 9 med 28%ig natronlut. Den organiske fase fraskilles; den inneholder 2-klor-6 , 7-dihydro-9 ,1 0-dimetoksy-7-metyl-4H-pyrimidino \_ 6 ,1 - a] - isokinolin-4-on.
En liten porsjon av denne organiske fase inndampes. Residuet oppløses i etylacetat og kromatograferes på silikagel.
Efter omkrystallisering fra etylacetat-heksan får man det rene produkt, smp. 219-220°C.
B. Fremstilling av produktet
Mesteparten av den i trinn A.c) oppnådde organiske fase tilsettes 100 ml 2,4,6-trimetylanilin, og det hele kokes i 20 timer under tilbakeløpskjøling. Oppløsningen inndampes derefter, og residuet oppløses i etylacetat og kromatograferes på silikagel. Rent 6,7-dihydro-9,10-dimetoksy-2-mesitylamino-7-metyl-4H-pyrimido [6 ,1 - a~] isokinolin-4-on isoleres som hydrokloridet, smp. 191-193°C, (80% utbytte), efter behandling med saltsyre.
Eksempel 2
Analogt med eksempel 1 ble fremstilt:
a) ved å gå ut fra 3 , 4-dimetoksy-a-metylf enetylamin over (3,4-dimetoksy-a-metylfenetyl)urinstoff, smp. 172°C,
og (3,4-dimetoksy-a-metylfenetyl)barbitursyre, smp. 162-164°C,
oppnås
6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido [6,1-a]isokinolin-4-on; smp. for hydrokloridet 199°C;
b) ved å gå ut fra 3 , 4-dimetoksy-|3 , 3-dimetylf enetylamin over (3,4-dimetoksy-3,B-dimetylfenetyl)urinstoff, smp. 152°C
og 3,4-dimetoksy-B,(3-dimetylfenetylbarbitursyre, smp. 172°C, oppnås
6,7-dihydro-9,10-dimetoksy-2-mesitylamino-7,7-dimetyl-4H-pyrimido [6 ,1-a] isokinolin-4-on, smp. for hydrokloridet 203-205°C.
Eksempel 3
18 g 6,7-dihydro-9,10-dimetoksy-2-mesitylamino-7-metyl-4H-pyrimido 1.6,1-a^ isokinolin-4-on kokes i 1,5 1 aceton i nærvær av 90 g kaliumkarbonat med 270 ml metyljodid i 2 timer Under til-bakeløpskjøling. Derefter foretas filtrering, og filtratet inndampes. Residuet oppløses i kloroform og renses kromatografisk på en silikagelkolonne. Man får 9,4 g rent 9,10-dimetoksy-3,7-dimetyl-2-mesitylimino-2 ,3,6, 7-tetrahydro-4H-pyrimido[_ 6 ,1 -a] - isokinolin-4-on, smp. 156-157°C. Det tilsvarende hydroklorid av dnene forbindelse smelter ved 224°C (dekomp.).
Eksempel 4
Analogt med eksempel 3 ble fremstilt:
a) ved å gå ut fra 6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido[6,1-a] isokinolin-4-on: 9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetra-hydro-4H-pyrimido [6 ,1-a]isokinolin-4-on, smp. for hydrokloridet 224°C; b) ved å gå ut fra 6,7-dihydro-9,10-dimetoksy-7,7-dimetyl-2- mesitylamino-4H-pyrimido [6,1-a] isokinolin-4-on: 9,10-dimetoksy-2-mesitylimino-2,3,6,7-tetrahydro-3,7,7-trimetyl-4H-pyrimido [6 ,1-a]isokinolin-4-on, smp. for hydrokloridet 192-194°C.
Eksempel 5
Analogt med eksemplene 1 og 3 ble fremstilt:
a) ved å gå ut fra 3-(3,4-dimetoksyfenyl)proylamin over [ 3-( 3 , 4-dimetoksyf enyl )propyl] urinstof f , smp. 1 65-1 66°C
og 1 - [3-(3,4-dimetoksyfenyl)propyl] barbitursyre, smp. 119 — 121°C, oppnås
10,11-dimetoksy-2-mesitylimino-3-metyl-2,3,7,8-tetrahydro-4H,6H-pyrimido [6,1-a] benzazepin-4-on, smp. for hydrokloridet 21 2-214°C;
b) ved å gå ut fra 3,4-dimetoksyfenetylamin over 3,4-dimetoksyfenetylurinstoff
og 1-(3,4-dimetoksyfenetyl)-5-metylbarbitursyre, smp. 164-165°C, oppnås
9,10-dimetoksy-1,3-dimetyl-2-mesitylimino-2,3,6,7-tetra-hydro-4H-pyrimido [6 ,1- a]isokinolin-4-on, smp. for hydrokloridet 160°C;
c) ved å gå ut fra 4-metoksy-3,3-dimetylfenetylamin over 4-metoksy-3,3-dimetylfenetylurinstoff, smp. 137°C
og 4-metoksy-3,3-dimetylfenetylbarbitursyre, smp. 175°C, oppnås
2-mesitylimino-10-metoksy-2,3,6,7-tetrahydro-3,7,7-trimetyl-4H-pyrimido [6 ,1 -a] isokinolin-4-on, smp. for hydrokloridet 216-217°C.
Eksempel 6
Analogt med eksemplene 1 og 3 ble fremstilt:
a) 1. 6,7-dihydro-9,10-dimetoksy-7-metyl-2-(o-toluidino)-4H-pyrimido [6 ,1-a]isokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2-(o-tolylimino)-2,3,6,7-tetrahydro-4H-pyrimido [6,1-a]isokinolin-4-on, smp. for hydrokloridet 192-193°C; b) 1. 6,7-dihydro-9,10-dimetoksy-7-metyl-2-(2,6-xylidino)-4H-pyrimidojjj, 1 -a] isokinolin-4-on og 2. 9,10 dimetoksy-3,7-dimetyl-2,3,6,7-tetrahydro-(2,6-xylyl-imino)-4H-pyrimido[6,1-a^isokinolin-4-on, smp. for hydrokloridet 241-242°C; c) 1. 6,7-dihydro-9,10-dimetoksy-2-(3,5-dimetoksyanilino)-7-metyl-4H-pyrimido[6,1-a]isokinolin-4-on og 2. 2,3,6,7-tetrahydro-9,10-dimetoksy-3,7-dimetyl-2-(3,5-dimetoksyfenylimino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 226°C; d) 1. 6,7-dihydro-9,10-dimetoksy-7-metyl-2-(3,4,5-trimetoksy-anilino)-4H-pyrimido[6,1-a^ isokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2,3,6,7-tetrahydro-2-(3,4,5-trimetoksyfenylimino)-4H-pyrimido [6,1-a]isokinolin-4-on, smp. for hydrokloridet 256-257°C; e) 1. 6,7-dihydro-9,10-dimetoksy-2-(p-fluoranilino)-7-metyl-4H-pyrimido [6 ,1- a]isokinolin-4-on og 2 . 2,3,6, 7-tetrahydro-9,10-dimetoksy-3,7-dimetyl-2-(p-fluor-fenylimino)-4H-pyrimido[6,1-al isokinolin-4-on, smp. for hydrokloridet 240°C; f) 1. 6,7-dihydro-9,10-dimetoksy-7-metyl-2-(2,4-xylidino)-4H-pyrimido[6,1-a] isokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2,3,6,7-tetrahydro-2-(2,4-xylylimino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 230-231°C; g) 1. 2-anilino-6,7-dihydro-9,10-dimetoksy-7-metyl-4H-pyrimido-[_ 6 ,1 -a] isokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2-fenylimino-2,3,6,7-tetrahydro-4H-pyrimido [_ 6 ,1 -a] isokinolin-4-on, smp. for hydrokloridet 232-233°C; h) 1. 6,7-dihydro-9,10-dimetoksy-2-(p-metoksyanilino)-7-metyl-4H-pyrimido[6,1-alisokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2-(p-metoksyfenylimino)-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 215°C; i) 1. 6,7-dihydro-9,10-dimetoksy-2-(m-fluoranilino)-7-metyl-4H-pyrimido[6,1-alisokinolin-4-on og 2. 9,10-dimetoksy-3,7-dimetyl-2-(m-fluorfenylimino)-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a}isokinolin-4-on, smp. for hydrokloridet 228-230°C; j)1. 2-(6-klor-2-toluidino)-6,7-dihydro-9,10-dimetoksy-7-metyl-4H-pyrimido[6,1-al isokinolin-4-on og 2. 2-(6-klor-2-tolylimino)-9,10-dimetoksy-3,7-dimetyl-2,3,6,7-tetrahydro-4H-pyrimido[6,1-alisokinolin-4-on, smp. for hydrokloridet 211-212°C; k)1 . 2-(2,6-dietylanilino)-6,7-dihydro-9,10-dimetoksy-7-metyl-4H-pyrimido [6 ,1-a^isokinolin-4-on og 2. 2-(2,6-dietylfenylimino)-9,10-dimetoksy-3,7-dimetyl-2,3,6,7-tetrahydro-4H-pyrimido [6 ,1-a]] isokinolin-4-on, smp. for hydrokloridet 196-197°C; 1)1 . 6,7-dihydro-2-(2,6-diisopropylanilino)-9,10-dimetoksy-7-metyl-4H-pyrimido jj), 1 - a] i sok i noi in-4-on og 2. 2-(2,6-diisopropylfenylimino)-9,10-dimetoksy-3,7-dimetyl-2 , 3 , 6 , 7-tetrahydro-4H-pyrimido[6 ,1 - a~\ isokinolin-4-on, smp. for hydrokloridet 233°C.
Eksempel 7
Analogt med eksemplene 1 og 3 ble følgende forbindelser fremstilt: a) ved å gå ut fra a-etyl-3,4-dimetoksyfenetylamin, smp. for hydrokloridet 150-152°C, 1. 6-etyl-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-4H-pyrimido [6 ,1 -a[]isokinolin-4-on, smp. for hydrokloridet 21 9°C, og 2. 6-ety1-9,10-dimetoksy-2-mesitylimino-3-metyl-2,3,6,7-tetrahydro-4H-pyrimido [6 ,1 - a~] isokinolin-4-on, smp. for hydrokloridet 207-209°C;
b) ved å gå ut fra 2-amino-3-(3,4-dimetoksyfenyl)butan,
1. 6,7-dihydro-9,10-dimetoksy-6,7-dimetyl-2-mesitylamino-4H-pyrimido^6,1-a^ isokinolin-4-on og 2. 9,10-dimetoksy-2-mesitylimino-2,3,6,7-tetrahydro-3,6,7-trimetyl-4-H-pyrimido[6 ,1-a]isokinolin-4-on, smp. for hydrokloridet 236-237°C; c) ved å gå ut fra 3,4-dietoksy-a'-metylf enetylamin, smp. for hydrokloridet 144-146°C; 1. 9,10-dietoksy-6,7-dihydro-2-mesitylamino-6-metyl-4H-pyrimido [_ 6 ,1 - a] isokinolin-4-on, smp. for hydrokloridet 208-21 0°C, og 2. 9,10-dietoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido \_ 6 ,1 - a~\ isokinolin-4-on, smp. for hydrokloridet 119-1 21°C, d) ved å gå ut fra 2,3-dimetoksy-a-metylfenetylamin,
8,9-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido [_6 ,1 - a~\ isokinolin-4-on, smp. for hydrokloridet 220°C; e) ved å gå ut fra a-metyl-3,4,5-trimetoksyfenetylamin
3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-9,10,11-trimetoksy-4H-pyrimido|j>,1-a] isokinolin-4-on, smp. for hydrokloridet 221°C; f) ved å gå ut fra a-metyl-3,4-metylendioksyfenetylurinstoff
3,6-dimetyl-2-mesitylimino-9,10-metylendioksy-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 300°C; g) ved å gå ut fra 3-(3,4-dimetoksyfenyl)butylamin over 3-(3,4-dimetoksyfenyl)urinstoff, smp. for hydrokloridet 87-89°C,
10,11-dimetoksy-3,8-dimetyl-2-mesitylimino-2,3,7,8-tetrahydro-4H-pyrimido [_ 6 ,1 - a~\ benzazepin-4-on, smp. for hydrokloridet 234-235°C; h) ved å gå ut fra (S)-3,4-dimetoksy-a-metylfenetylamin over 1 -[(S)-3,4-dimetoksy-a-metylfenetyl] barbitursyre, smp. 178-1 79°C,
[a]D+ 93,6° (c = 1%, metanol),
1 . (S)-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido [ 6 ,1 -a]isokinolin-4-on, smp. for hydrokloridet 196°C, [a]D+ 43,3° (c = 2%, metanol), og 2. (S)-9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido\_ 6 ,1- a]isokinolin-4-on, smp. for hydrokloridet 196°C, [pt3D- 13° (c = 2%, vann); i) ved å gå ut fra (R)-3,4-dimetoksy-a-metylfenetylamin over 1 - [(R)-3,4-dimetoksy-a-metylfenetyl]barbitursyre, smp. 1 77-1 78°C, [a] - 92,1° (c = 1%, metanol), 1 . (R)-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido[6,1-a] isokinolin-4-on, smp. for hydrokloridet 196°C, [.°0D - 39,6° (c = 2%, metanol), og 2. (R)-9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido [6 ,1-a] isokinolin-4-on, smp. for hydrokloridet 1 95-1 96°C, [a]D+ 13° (c = 2,5%, vann); j) ved å gå ut fra 1-[(S)-3,4-dimetoksy-a-metylfenetyl] barbitursyre 1 . (S)-6,7-dihydro-9,10-dimetoksy-6-metyl-2-(2,6-xylidino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 182-183°C; [ot] + 45,6° (c = 0,5, metanol), og 2. (S)-9,10-dimetoksy-3,6-dimetyl-2,3,6,7-tetrahydro-2-(2,6 - xylylimino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 167-168°C, [a] + 30,1° (c = 2%, metanol); k) ved å gå ut fra ( S )-3 , 4-dimetoksy-(3-metylf enetylamin over [(S)-3,4-dimetoksy-3-metylfenetyl]urinstoff, smp. 186-187°C, [a]D- 41° (c = 1%, metanol),
(R)-9,10-dimetoksy-3,7-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido [6 ,1-a]isokinolin-4-on, smp. for hydrokloridet 219-221°C, [a]D- 18,0° (c = 2%, metanol); 1) ved å gå ut fra (R)-3,4-dimetoksy-3-metylfenetylamin over [(R)-3 , 4-dimetoksy-B-metylf enetyl] urinstof f , smp. 1 87-1 88°C,
[a]D+ 45° (c = 1%, metanol),
(S)-9,1 0-dimetoksy-3,7-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimidoj^6 ,1-a] isokinolin-4-on, smp. for hydrokloridet 220-221°, [a]D+13° (c = 2%, metanol),
m) ved å gå ut fra (S)-a-etyl-3,4-dimetoksyfenetylamin over (S)-a-etyl-3,4-dimetoksyfenetylurinstoff, smp. 135-137°C,
[a]D+ 11,3° (c = 1%, metanol),
1 . (S )-6-etyl-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-4H-pyrimido[6,1- a]isokinolin-4-on, smp. for hydrokloridet 189-193°C, [a]D+ 62,5° (c = 2%, metanol), 2. (S)-6-ety1-9,10-dimetoksy-2-mesitylimino-3-metyl-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 166-170°C, [a]D+ 47,4° (c = 2%, metanol), 3. (S)-6-etyl-6,7-dihydro-9,10-dimetoksy-2-(2,6-xylidino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 171-175°C, [a]D+ 58,0° (c = 2%, metanol), og 4. (S)-6-etyl-9,10-dimetoksy-3-metyl-2,3,6,7-tetrahydro-2-(2,6-xylylimino)-4H-pyrimido[6,1-a]isokinolin-4-on, smp. for hydrokloridet 1 48-1 52°C, [ct]D+ 49,4° (c = 2%, metanol).
Eksempel 8
Analogt med eksempel 3 ble under anvendelse av 1-propyljodid istedenfor metyljodid fremstilt 9,10-dimetoksy-2-mesitylimino-7-metyl-3-propyl-2,3,6,7-tetrahydro-4H-pyrimido [6,1-a]isokinolin-4-on, smp. for hydrokloridet 152-154°C.
Claims (10)
1. Fremgangsmåte for fremstilling av pyrimidon-derivater med formelen
hvor n betyr tallet 1 eller o,
1 2
X, A og A betyr metylen som eventuelt er mono- eller di-lavere-alkylert ,
eller X betyr nitrogen som eventuelt er lavere-alkylert, R betyr hydrogen eller lavere-alkyl, og Y sammen med Z 5
en gruppe =NR ,
eller R sammen med Z betyr en N-C-binding, og Y en gruppe
-N(H)R <5> ,
1 2 3
R , R og R betyr hydrogen, lavere-alkyl eller lavere-alkoksy ,
eller to nabostilte R 1, R 2 eller R 3 betyr metylendioksy eller etylendioksy,
R <4> betyr hydrogen eller lavere-alkyl,
5 6 7 R betyr etyl som eventuelt er substituert med R , R ogR<8> ,
6 7 8
R , R og R er klor, fluor, brom, lavere-alkyl eller
-alkoksy,
idet hvis R 4 er hydrogen og n=0, er minst e«n av metylgruppene 1 2
A og A mono- eller di-lavere-alkylert,
og fysiologisk forlikelige salter derav, karakterisert ved at,a) en forbindelse med formelen
hvor Y <1> er klor eller brom, og de øvrige symboler har den ovenfor angitte betydning,
omsettes med et amin med formelen R 5 , hvor R 5 har den ovenfor angitte betydning,
b) en fremstilt forbindelse med formel I hvor R betyr hydrogen, og Y sammen med Z er en gruppe =NR~*, eller hvor R sammen med Z danner en N-C-binding og Y er en gruppe -N(H)R 5 , og R 5 har den ovenfor angitte betydning, omsettes eventuelt med et lavere-alkylhalogenid,
c) produktet fra trinn a) eller b) isoleres i form av en fri base med formel I eller et fysiologisk forlikelig salt derav.
2. Fremgangsmåte ifølge krav 1, karakterisert ved at man fremstiller forbindelser med formel I, hvor X,
1 2
A og A er metylen som eventuelt er mono- eller dimetylert eller X betyr nitrogen som eventuelt er metylert, og R 6 , R <7> og R <g> betyr klor, brom, lavere-alkyl eller -alkoksy.
3. Fremgangsmåte ifølge krav 1 eller 2, karakterisert ved at man fremstiller forbin-1 2 3 deiser med formel I, hvor R betyr hydrogen, og R og R betyr lavere-alkoksy, særlig metoksy, i para-stilling til de angulære C-atomer i fenylringen.
4. Fremgangsmåte ifølge krav 1, 2 eller 3, karakterisert ved at man fremstiller forbindelser med formel I, hvor n er 0 eller 1, X er metylen, én av 1 2
A og A er metylen og den annen er mono-metylert metylen.
5. Fremgangsmåte ifølge krav 4, karakterisert ved at man fremstiller forbindelser med formel I hvor C-atomet i en mono-metylert metylengruppe har R-konfigurasjonen resp. C-atomet i en mono-metylert metylengruppe A 2har S-konfi-gurasj onen.
6. Fremgangsmåte ifølge ett av kravene 1 - 5, karakterisert ved at man fremstiller forbindelser hvor R betyr hydrogen eller metyl, eller R sammen med Z danner en N-C-binding.
7. Fremgangsmåte ifølge ett av kravene 1 - 6, karakterisert ved at man fremstiller forbindelser med formel I hvor R <4> betyr hydrogen.
8. Fremgangsmåte ifølge ett av kravene 1 - 7, karakterisert ved at man fremstiller forbindel-5
ser med formel I hvor R er mesityl eller 2,6-xylyl.
9. Fremgangsmåte ifølge ett av kravene 1 - 8, karakterisert ved at man fremstiller forbindel-1 2 3 ser med formel I hvor R betyr hydrogen, og R og R betyr lavere-alkoksy, særlig metoksy, i para-stilling til de angulære C-atomer i fenylringen, n er 0 eller 1, X er metylen, én av A og A 2er metylen og den annen er mono-metylert metylen, idet C-atomet i en mono-metylert metylengruppe A 1 har R-konfigurasjonen resp. C-atomet i en mono-metylert metylengruppe A 2 har S-konfigurasjonen, R betyr hydrogen eller metyl, eller R sammen 4 5 med Z danner en N-C-binding, R er hydrogen, og R er mesityl eller 2,6-xylyl.
10. Fremgangsmåte ifølge krav 1, karakterisert ved at man fremstiller en forbindelse valgt fra:
(S)-9,10-dimetoksy-3,6-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isokinolin-4-on,
(S)-6-ety1-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-4H-pyrimido[6,1-a]isokinolin-4-on,
(S)-6-etyl-9,10-dimetoksy-2-mesitylimino-3-mety1-2,3,6,7-tetrahydro-4.H-pyrimido [.6,1 -a] isokinolin-4-on,
(S)-6-etyl-6,7-dihydro-9,10-dimetoksy-2-(2,6-xylidino)-4H-py r imi do \_ 6 ,1 -a] isokinolin-4-on,
(S)-6-etyl-9,10-dimetoksy-3-metyl-2,3,6,7-tetrahydro-2-(2,6-xylylimino)-4H-pyrimido[6,1-a] isokinolin-4-on,
6,7-dihydro-9,10-dimetoksy-2-mesitylimino-6-metyl-4H-pyrimido [6,1- a]isokinolin-4-on,
9,10-dimetoksy-3,6-dimetyl-2-mesitylamino-2,3,6,7-tetra-hydro-4H-pyrimido [6 ,1-a]isokinolin-4-on,
10,11-dimetoksy-2-mesitylimino-3-metyl-2,3,7,8-tetrahydro-4H, 6H-pyrimido [6 ,1 -a] benzazepin-4-on,
(S)-6,7-dihydro-9,10-dimetoksy-2-mesitylamino-6-metyl-4H-pyrimido [6 ,1 -aj isokinolin-4-on,
(S)-6,7-dihydro-9,10-dimetoksy-6-metyl-2-(2, 6-xylidino)-4H-pyrimido [6 ,1 - a] isokinolin-4-on,
(S)-9,10-dimetoksy-3,6-dimetyl-2,3,6,7-tetrahydro-2-(2,6-xylylimino ) -4H-pyrimido jj5,1 -a] isokinolin-4-on , og
(R)-9,10-dimetoksy-3,7-dimetyl-2-mesitylimino-2,3,6,7-tetrahydro-4H-pyrimido[6 ,1-a]isokinolin-4-on.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH244283 | 1983-05-05 | ||
CH139284 | 1984-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO841780L true NO841780L (no) | 1984-11-06 |
Family
ID=25687524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO841780A NO841780L (no) | 1983-05-05 | 1984-05-04 | Fremgangsmaate for fremstilling av nye pyrimidon-derivater |
Country Status (16)
Country | Link |
---|---|
US (1) | US4581172A (no) |
EP (1) | EP0124893A3 (no) |
AU (1) | AU2751084A (no) |
CA (1) | CA1237429A (no) |
CS (1) | CS243486B2 (no) |
DK (1) | DK198784A (no) |
ES (1) | ES8505369A1 (no) |
FI (1) | FI841619A (no) |
HU (1) | HUT34025A (no) |
IL (1) | IL71711A (no) |
MC (1) | MC1600A1 (no) |
NO (1) | NO841780L (no) |
NZ (1) | NZ207981A (no) |
PH (1) | PH19219A (no) |
PT (1) | PT78549B (no) |
ZW (1) | ZW6284A1 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0134984B1 (en) * | 1983-07-16 | 1988-07-13 | Beecham Group Plc | Benzazepine and benzoxazepine derivatives |
GB9707251D0 (en) * | 1997-04-10 | 1997-05-28 | Smithkline Beecham Plc | Novel method and compounds |
NZ514158A (en) * | 1999-03-31 | 2000-03-29 | Vernalis Ltd | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
US7169907B2 (en) * | 2002-03-01 | 2007-01-30 | Roche Diagnostics Operations, Inc. | Derivatives, immunogens, and antibodies for detecting ecstasy-class drugs |
US7501512B2 (en) * | 2003-07-08 | 2009-03-10 | Smithkline Beecham Corporation | Chemical compounds |
GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
WO2017016960A1 (en) * | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues |
GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
CN112368281B (zh) | 2018-07-13 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 作为pde3/pde4双重抑制剂的三并环类化合物 |
AU2021207159A1 (en) * | 2020-01-15 | 2022-08-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of PDE3/PDE4 dual inhibitor and use thereof |
AU2021208129A1 (en) * | 2020-01-15 | 2022-08-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ185900A (en) * | 1976-12-10 | 1981-04-24 | Hoechst Ag | Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines |
DE2720085A1 (de) * | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
FI64370C (fi) * | 1977-05-05 | 1983-11-10 | Hoechst Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat |
DE2847693A1 (de) * | 1978-11-03 | 1980-05-22 | Hoechst Ag | Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen |
DE3135831A1 (de) * | 1981-09-10 | 1983-04-28 | Hoechst Ag, 6230 Frankfurt | 9,10-substituierte 2-mesitylimino-3-alkyl-3,4,6,7-tetrahydro-2h-pyrimido(6,1-a)isochinolin-4-one, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
-
1984
- 1984-04-13 ZW ZW62/84A patent/ZW6284A1/xx unknown
- 1984-04-13 CA CA000451949A patent/CA1237429A/en not_active Expired
- 1984-04-17 DK DK198784A patent/DK198784A/da not_active Application Discontinuation
- 1984-04-25 US US06/603,793 patent/US4581172A/en not_active Expired - Fee Related
- 1984-04-25 FI FI841619A patent/FI841619A/fi not_active Application Discontinuation
- 1984-04-27 NZ NZ207981A patent/NZ207981A/en unknown
- 1984-04-30 AU AU27510/84A patent/AU2751084A/en not_active Abandoned
- 1984-05-01 IL IL71711A patent/IL71711A/xx not_active IP Right Cessation
- 1984-05-02 MC MC841703A patent/MC1600A1/xx unknown
- 1984-05-02 HU HU841693A patent/HUT34025A/hu unknown
- 1984-05-02 CS CS843255A patent/CS243486B2/cs unknown
- 1984-05-04 PH PH30644A patent/PH19219A/en unknown
- 1984-05-04 NO NO841780A patent/NO841780L/no unknown
- 1984-05-04 PT PT78549A patent/PT78549B/pt unknown
- 1984-05-04 ES ES532172A patent/ES8505369A1/es not_active Expired
- 1984-05-04 EP EP84105052A patent/EP0124893A3/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NZ207981A (en) | 1987-05-29 |
EP0124893A3 (de) | 1987-11-11 |
ES532172A0 (es) | 1985-06-01 |
FI841619A (fi) | 1984-11-06 |
IL71711A0 (en) | 1984-09-30 |
ES8505369A1 (es) | 1985-06-01 |
HUT34025A (en) | 1985-01-28 |
FI841619A0 (fi) | 1984-04-25 |
IL71711A (en) | 1987-08-31 |
PT78549A (en) | 1984-06-01 |
EP0124893A2 (de) | 1984-11-14 |
AU2751084A (en) | 1984-11-08 |
ZW6284A1 (en) | 1985-10-30 |
DK198784A (da) | 1984-11-06 |
PT78549B (en) | 1986-09-15 |
DK198784D0 (da) | 1984-04-17 |
US4581172A (en) | 1986-04-08 |
CS325584A2 (en) | 1985-08-15 |
PH19219A (en) | 1986-02-12 |
CS243486B2 (en) | 1986-06-12 |
MC1600A1 (fr) | 1985-05-09 |
CA1237429A (en) | 1988-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5219859A (en) | Indole derivatives, preparation processes and medicinal products containing them | |
NO851862L (no) | Fremgangsmaate ved fremstilling av nye pyrrolobenzimidazoler | |
IE870345L (en) | Indolizine derivatives | |
NZ201294A (en) | Imidazoquinoxaline derivatives | |
US5223503A (en) | 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents | |
US4782055A (en) | Imidazopyridine compounds useful in the treatment of ulcers | |
SU999972A3 (ru) | Способ получени производных пиридо-(1,2-а) пиримидина или их фармацевтически приемлемых солей,или их оптически активных изомеров | |
KR100717489B1 (ko) | 피리도피리미디논 화합물, 이의 제조 방법 및 이를함유하는 약제 조성물 | |
NO841780L (no) | Fremgangsmaate for fremstilling av nye pyrimidon-derivater | |
DK165744B (da) | Thienopyrimidinderivater, fremgangsmaader til fremstilling deraf og farmaceutiske praeparater | |
CZ94098A3 (cs) | Tertahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem | |
US4882329A (en) | Alkoxyphenylindolinone derivatives, medicaments containing them and their use | |
FI71936B (fi) | Foerfarande foer framstaellning av neuroleptiskt aktiva 2-substituerade-8-fluor-5-(4-fluorfenyl)-2,3,4,4a 5,9b-hexahydro-4a 9b-trans-1h-pyrido/4,3-b/indolderivat | |
US5635511A (en) | Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds. | |
EP0273401B1 (en) | Isoindolin-1-one derivative and antiarrhythmic agent | |
US5212186A (en) | Cardioactive pyrrolobenzimidazoles | |
JPH03106875A (ja) | 1―(3―ピリジルメチル)フタラジン誘導体 | |
NO171908B (no) | Analogifremgangsmaate for fremstilling av 4-(aroylamino)piperidinbutanamidderivater | |
JPH05117273A (ja) | 医薬化合物 | |
IE55377B1 (en) | 1,5-diphenylpyrazolin-3-one compounds,method for preparing them,and pharmaceutical compositions containing these compounds | |
US5025016A (en) | Pyrimidine-thioalkyl pyridine derivatives, medicaments containing these compounds, and method of treatment | |
US4258188A (en) | 2-(1-Piperazinyl)-cycloheptimidazole derivatives | |
AU597233B2 (en) | Bicyclic lactams, processes for their preparation and their use and formulations containing these compounds | |
US4355031A (en) | 2,3-Dihydro-3-[4-(substituted)-1-piperazinyl]-1H-isoindol-1-ones | |
US3907800A (en) | Derivatives of spiro-{8 piperidine-4{40 :6-(3,2-a)-thiazolopyrimidine{9 |